NCT05873764View on ClinicalTrials.gov

A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 25, 2022

Primary Completion Date

July 12, 2022

Study Completion Date

July 12, 2022

Conditions
Respiratory Syncytial Virus Infections
Interventions
DRUG

200 mg RV521/78 µCi [ 14C]-RV521.

200 mg RV521/78 µCi \[ 14C\]-RV521

Trial Locations (1)

21201

Pharmaron Clinical Pharmacology Center, Baltimore

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05873764 - A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants | Biotech Hunter | Biotech Hunter